Immunomodulation of Homeopathic Thymulin 5CH in a BCG-Induced Granuloma Model by Bonamin, Leoni Villano et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 686018, 15 pages
http://dx.doi.org/10.1155/2013/686018
Research Article
Immunomodulation of Homeopathic Thymulin 5CH in
a BCG-Induced GranulomaModel
Leoni Villano Bonamin,1, 2, 3 Cesar Sato,1, 3 Ruggero Zalla Neto,1 Graziela Morante,1
Thayná Neves Cardoso,1 Fabiana Rodrigues de Santana,1 Cideli de Paula Coelho,1, 2
Lika Osugui,4 Ana Flavia Popi,4 Elizabeth Cristina Perez Hurtado,1, 4 andMarioMariano1, 4
1 Research Center of Universidade Paulista, Rua Dr. Bacelar 1212, 5th Floor, 04026-002 São Paulo, SP, Brazil
2 Laboratory of Veterinary Pathology, Universidade de Santo Amaro, São Paulo, SP, Brazil
3 Instituto de Ensino, Pesquisa e Desenvolvimento Royal, São Roque, SP, Brazil
4 Laboratory of Immunology, Universidade Federal de São Paulo, São Paulo, SP, Brazil
Correspondence should be addressed to Leoni Villano Bonamin; leonibonamin@gmail.com
Received 9 October 2012; Revised 3 December 2012; Accepted 20 December 2012
Academic Editor: Ke Ren
Copyright © 2013 Leoni Villano Bonamin et al.is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
e present study analyzed the immune modulation mechanisms of thymulin 5CH in a granuloma experimental model. Male
adult Balb/c mice were inoculated with BCG into the footpad to induce granuloma, which was quantitatively evaluated. e
phenotypic characterization of phagocyte, T- and B-lymphocyte populations in the peritoneum, and local lymph node was done
by �ow cytometry. During all experimental periods, thymulin 5CH and vehicle (control) were given ad libitum to mice, diluted
into the drinking water (1.6×10−17 M). Aer 7 days from inoculation, thymulin-treatedmice presented reduction in the number of
epithelioid cytokeratine-positive cells (𝑃𝑃 𝑃 0.0001) in the lesion, in relation to young phagocytes. Aer 21 days, the diﬀerentiation
of B1 peritoneal stem cells into phagocytes reached the peak, being higher in thymulin-treated mice (𝑃𝑃 𝑃 0.0001). Simultaneously,
the score of infected phagocytes in the lesion decreased (𝑃𝑃 𝑃 0.001), and the number of B1-derived phagocytes, CD4+ and CD8+ T
lymphocytes in the local lymph node increased in relation to control (𝑃𝑃 𝑃 0.0001). No diﬀerence was seen on the CD25+ Treg cells.
e results show that thymulin 5CH treatment is able to improve the granuloma in�ammatory process and the infection remission,
by modulating local and systemic phagocyte diﬀerentiation.
1. Introduction
e experimental demonstration of the eﬀects of high diluted
homeopathic medicines has been the focus of several studies
using animal models in the last ten years, providing enough
substrate to recent systematic reviews [1–4], including those
about immunology and homeopathy [5–10]. Among these
studies, a wide range of eﬀects related to the administration of
endogenous substances prepared as homeopathic medicines
has been observed by our group in diﬀerent animal species
[11–14].
ymulin is an endogenous peptide with immune reg-
ulatory function that has been studied as homeopathic
high dilutions since the eighties [15–18]. In these studies,
several evidences were highlighted about the modulation
property of homeopathic thymulin prepared at 5CH potency,
including seasonal variations and variable eﬀects according
to individual previous status [17, 18]. In C57BL/6, high
diluted thymulin (10−11mg/animal) reduced the cell immune
response. Nonetheless, in NZB mice, that develop lupus
spontaneously, the same thymulin concentration decreased
the humoral thymus-dependent response, decreasing self-
immunity potential of lymphocytes harvested from these
animals [16].
Recent studies made by our group showed that thymulin
5CH oﬀered ad libitum into the drinking water to mice
bearing Ehrlich tumor, decreased partially the suppression
of the bone marrow aer cyclophosphamide treatment, and
increased bonemetaplasia area into the tumor [19]. In broiler
chicken, thymulin 5CH oﬀered into the drinking water since
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the �rst day of life improved the weight gain, survival,
and productivity indexes at slaughter time [13]. Important
to point out that oﬀering homeopathic medicines into the
drinkingwater represents a good, cheap, and easy tool to treat
farm animals [20].
ymulin is produced by the thymus epithelial compo-
nent and is composed by nine aminoacids (Glp-Ala-Lys-Ser-
Gln-Gly-Gly-Ser-Asn-OH). It is important in several steps
of T-lymphocyte maturation [21, 22] and in several neuro-
endocrine functions, including sexualmaturity, reproduction
[23, 24], and neuroprotective functions [25, 26]. Zinc is an
important cofactor in thymulin physiological activity, being
controlled by metallothioneins [24, 27]. Several pathological
processes can be in�uenced by physiological concentrations
of thymulin, such as T cell and phagocyte function recovery
in immune suppressed animals [28, 29], balance of cytokines
[29–31], and improvement of regenerative functions [32].
However, all these eﬀects refer to physiological quantities of
serum thymic factor that are quite higher than those found in
homeopathic preparations and their eﬀects cannot be directly
associated. is fact points toward to an important question:
are the immune modulation eﬀects of homeopathic serum
thymic factor demonstrable?
e aim of the present study is to demonstrate the mod-
ulation properties of homeopathic 5CH thymulin using the
experimental BCG-induced granuloma model. is model
was chosen due to its well-established process to study
immune-mediated chronic in�ammation and the role of the
pertinent cells, including phagocytes, T, B1, and B2 cells [33–
38].
2. Materials andMethods
2.1. Animals. Speci�c pathogen free (SPF) adult male
BALB/c mice (25 to 35 g of body weight) were obtained
from a reference rodent biotery CEDEME/UNIFESP, São
Paulo, and maintained standing in the Research Center SPF
biotery of Paulista University during at least seven days
before any experimental procedure, due to environmental
adaptation. During all experimental period, animals were
kept in conventional microisolators (Techniplast), being �ve
animals per cage. Sterile food and water were oﬀered ad
libitum. e controlled temperature was 22 ± 2∘C and light
was programmed to be 12 hours light, from06:30 h to 18:30 h.
e number of air cycles per hour inside cages was 75/hour,
being the humidity between 50 and 65%.
2.2. ymulin Preparation. e thymulin 5CH was prepared
from the stock commercial homeopathic preparation y-
mulin 4CH obtained from Boiron Brasil Laboratories, which
was prepared from the zinc free synthetic peptide or serum
thymic factor (MW = 858.85), whose purity degree was
98.66% (according to the supplier).e dilution and stocking
techniques were done according to the French Pharmacopeia
for homeopathic products, which means that the �rst 1 : 100
dilution (w/v) of pure serum thymic factor was used to
produce the 1CH potency aer 100 succussions; thus, 1 : 100
dilution (v/v) plus 100 succussions of 1CH was used to
A
B
F 1: Photomicrograph of a popliteal lymph node from a
thymulin 5CH treatedmouse, aer 21 days of BCG inoculation.e
major axis (𝐵𝐵) represents the follicle diameter and theminor axis (𝐴𝐴)
represents the germinal center. HE staining, magni�cation 1 : 200.
produce 2CH. e 3 and 4CH potencies were prepared
similarly. e vehicle used was 70% hydroalcoholic solution
and the �nal product was stocked at room temperature.
e disposable thymulin 5CH potency solution was
prepared just before use, diluting 1 : 100 the ymulin 4CH
matrix into 15mL of 30% hydroalcoholic solution, using
conventional amber �asks and an automatic mechanical
system to perform 100 succussions (Autic). A parallel similar
preparation was done using only succussed 30% hydro-
alcoholic solution, to be oﬀered to the control (vehicle) mice.
All technical procedures were in accordance to the
Brazilian Homeopathic Pharmacopeia, 2nd Edition and to
the French Pharmacopeia-Homeopathy, 6th Edition.
To be sure that there was no zinc contamination of
medicines, both thymulin 5CH and vehicle (succussed 30%
hydroalcoholic solution) samples were sent to a certi�ed
laboratory (CBO Analysis, Brazil) in order to measure its
quantity. No signi�cant amount of zinc was found in both
vials.
2.3. Blinding. Aer the drug preparations, another techni-
cian who did not participate of the experimental procedures
changed the labels of each �ask to another written A or B, and
the same codes were written in a sheet of paper together with
the original labels. is sheet was closed in a sealed envelope
and kept up to the end of statistical analysis, when codes were
broken.
2.4. Treatment. Mice received A or B treatment in a free
access into the drinking water. us, 0.1mL of A or B prepa-
ration (thymulin 5CHor vehicle 5CH)wasmixed regularly to
250mL of drinking water into an appropriate sterile bottle,
in order that the �nal theoretical thymulin concentration
oﬀered to mice was 4 × 10−13M. is concentration was
chosen based on that previously tested by us, using broiler
chickens [13]. e water and the added medicine were
replaced daily, during all experimental period, from the day
of BCG inoculation to the day of mice necropsy.
Each group (A or B) was composed by 10 to 15 mice,
according to the experimental time and procedure.
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Score Description Photomicrograph
1 Rare cytoplasm bacilli 
 
2 Mild quantity of cytoplasm 
bacilli 
 
3 Nonmeasurable quantity of 
cytoplasm bacilli 
 
F 2: �e score dia�ram o� BC� p�a�ocytosis in macrop�a�es located in t�e BC� inoculation site. �� stainin�� ma�ni�cation � : ����.
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F 3: Continued.
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F 3: (a) Illustrative scattering diagram representing the percentage, distribution, and selection of B-cells populations in Flow cytometry
of peritoneal washing �uid harvested from a control mouse. (A) lymphocyte and phagocyte gates identi�ed on the basis of cell size (𝑦𝑦-axis)
and lumpiness (𝑥𝑥-axis); (B) from the lymphocyte gate, a secondary diagram was extracted representing B1 (CD19+ CD23−) and B2 (CD19+
CD23+) cells; (C) from the phagocyte gate, another secondary diagram was extracted, representing B1 derived phagocytes—BDP (CD11b+
CD19+) and mature phagocytes—MP (CD11b+ CD19−). Graphs obtained from Flow Jo 8.7 soware. (b) Illustrative scattering diagram
representing the distribution and selection of B-cells populations in Flow cytometry of local lymph node cell suspension from a thymulin 5CH
treated mouse. (A) lymphocyte gate identi�ed aer the cell size (𝑦𝑦-axis) and lumpiness (𝑥𝑥-axis); (B) from the lymphocyte gate, a secondary
diagram was extracted representing B1 (CD19+ Cd11b+) cells; (C) from the B1 gate, another secondary diagram was extracted, representing
B1a (CD11b+ CD5+) cells. Graphs obtained from Attune 1.2 soware. (c) Illustrative scattering diagram representing the distribution and
selection of T-cell subpopulations in Flow cytometry of lymph node cell suspension, from a thymulin 5CH treated mouse. e diagram was
extracted from the lymphocyte gate. e predominant population was CD8+ cells (R14). Graphs obtained from Attune 1.2 soware.
1
1.5
2
1 2 4 7 10 14 16 21
(m
m
)
Days
Paw thickness
ymulin
Control
MANOVA, = 0.01 rel control
F 4: Evaluation of gross pathology (mean/standard deviation)
in function of time of the granuloma size in the footpad of mice
treated or not with thymulin 5CH.e paw thickness was measured
with a micrometer. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, MANOVA.
2.5. BCG Inoculation and Observation of Lesions. e
Calmette-Guérin bacilli (Vacina-BCG, Brazil) were supplied
by Butantan Institute, São Paulo, containing 2 × 𝑃𝑃6 viable
bacteria (CFU) by milligram of a lyophilized powder. e
powder was diluted into apyrogenic sterile saline to get 2×𝑃𝑃5
CFU in 50 𝜇𝜇L at the moment of inoculation. e inoculation
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F 5: Evaluation of BCG infection scores in function of time
obtained from Ziehl-Neelsen stained slides. Twenty phagocytes per
�eld were analyzed by two independent observers, in blind. ∗𝑃𝑃 𝑃
𝑃𝑃𝑃5, Mann-Whitney, and in relation to control. Data represent
mean and standard deviation.
was made in the subcutaneous tissue of the le footpad of
mice, using an ultra-�ne shot (BD Medical, USA).
Before inoculation, at zero time, the paw thickness was
measured by a digital micrometer (Mitutoyo IP65, Japan).
en, regular measurements were made in the subsequent
days to analyze the macroscopic in�ammation evolution.
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(a) (b)
F 6: Photomicrography of granuloma at the 7 day aer BCG inoculation into subcutaneous tissue. Note the presence of epithelioid cells
(arrows) predominantly in the control group (a) and young phagocytes in thymulin 5CH treated group (b). Hematoxylin-eosin, magnitude
1 : 100.
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F 7: Cytokeratin positive phagocytes per �eld (mean) in the
footpad, in function of time. Ten �elds were counted per slide. ∗𝑃𝑃 𝑃
0.01, Mann-Whitney, in relation to control.
e granuloma growth and the respective local and systemic
immunological parameters were studied aer 7, 14, and 21
days aer BCG inoculation, when batches of animals were
euthanized in a CO2 chamber. e paw, spleen, popliteal
local lymph node, and peritoneal �uid were harvested and
manipulated according to speci�c experimental procedures.
2.6. Histopathology and Histomorphometry. e subcuta-
neous tissue of the paw, the spleen, and the local popliteal
lymph node were �xed in 10% buﬀered formalin for no
more than 24 hours to avoid antigen masking. e histo-
logical procedures were made according to the conventional
hematoxylin-eosin (HE), Ziehl-Neelsen (ZN), Pearls (P), and
immunohistochemical staining procedures.
F 8: Photomicrography of cytokeratin positive phagocytes in
the footpad. 7 day aer BCG inoculation. Early epithelioid diﬀer-
entiation is seen in positive cells (arrows). Immunohistochemistry,
magnitude 1 : 1000.
From HE stained slides, a qualitative-descriptive analysis
of the granuloma structure was made for the footpad and
a quantitative analysis of the follicle diameter (𝐵𝐵) and the
respective germinal center (𝐴𝐴) of the local lymph node was
made using histometry technique (Figure 1). In this case the
major axis of each structure was measured using a 20 times
objective lens and a special 10x ocular lens, graduated by a 100
points scale, being 100 equal to 1mm. e �nal percentage
values were obtained by the following formula:
𝑃𝑃 𝑃
𝐴𝐴 𝐴 100
𝐵𝐵
. (1)
Since the descriptive analysis of spleen stained by HE
method revealed a trend in treated animals to present bigger
follicle area and an important quantity of golden pigment,
suggestive of hemosiderin, two speci�c histometric analyses
were made in this case: (a) an additional Pearls staining
method speci�c for iron pigments was used in the samemate-
rial to analyze the number of positive macrophages per �eld
in the spleen parenchyma, using a 40x objective. Ten random
�elds were analyzed per slide� (b) the mean area of spleen
follicles per slide was calculated using photomicrographs of
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F 9: Histomorphometric analysis of germinal center/follicle
diameter ratio (percentage) of the local lymph node. 21st day aer
BCG inoculation into the footpad. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, student “t” test.
HE stained slides at magni�cation 1 : 100 and the Image �
soware for Windows.
From the slides stained by ZN method, the histometry
was made by scores representing the quantity of bacilli
into the phagocyte cytoplasm. Twenty macrophages by �eld
were randomly analyzed using a 1000x immersion objective
and scores were attributed to each cell by two independent
observers to avoid subjective bias in the analysis (Figure 2).
2.7. Immunohistochemistry and Histomorphometry. All sam-
ples of subcutaneous tissue presenting granuloma were pre-
pared with a 5 microns paraﬃn embedded tissue slices and
paraﬃn removal was made through two baths in absolute
xylol and two baths in absolute alcohol, three minutes each.
Slides were, then, washed in current water.
e antigen retrieving was made using heat treatment
into citrate buﬀer (DAKO), using an electric pot at 80∘C
(PANASONIC) for twentyminutes.en, slides were washed
in PBS, pH� 7.2 (SIGMA), during �ve minutes in agitation,
dried, and the tissue sample was delimited with a Pap-
pen (AbCAM). e endogenous peroxidase activity was
blocked by slides incubation in 5% H2O2 in methanol,
during �een minutes at room temperature. Aer a new
washing in PBS, slides were treated with 2.5% of normal
horse serum (VECTOR) during twenty minutes at room
temperature for blocking of unspeci�c antigen adsorption
sites and tissues were immediately treated with the primary
antibody, whose dilution are described in Table 1. is
incubation was made at 4∘C, overnight, in a humid chamber.
All dilutions of primary antibody were made using speci�c
diluent for immunohistochemistry (DAKO).
In the day aer, cuts were washed in PBS (SIGMA)
for six minutes and treated with the polymer-peroxidase
conjugated secondary antibody (VECTOR), for rat or rabbit
IgG, according to the origin of the primary antibody. is
incubation lasted 30 minutes, at room temperature. Aer
new washing in PBS, they were exposed to DAB (DAKO) for
few seconds until the appearance of the brown color, washed
in tap water, counter-stained with Harris hematoxylin, and
mounted. e negative control of reactions was made by
changing the primary antibody by the diluent alone before
incubation. e positive control was made using mouse
lymphoid tissue samples to test leukocytes markers and
the epidermis itself, for testing the anticytokeratin antibody
reactivity.
2.8. Histomorphometry. e histomorphometry was per-
formed to better identify and quantify immune cells (Table 1)
in the lesion, since the HE observation was only descriptive
and the �ow cytometry of paw subcutaneous tissue cell sus-
pension was not possible to be done, due to the impossibility
to de�ne cell populations with a minimal number to make
them recognizable, even if a pool of several footpads cell
suspension was done.
e evaluation of the chronic in�ammation in the inocu-
lated subcutaneous tissue by the incidence of speci�c leuko-
cyte subsets was made by counting the number of positive
cells per �eld for each marker (Table 1), in which ten random
�elds were chosen in the connective tissue of the footpad
and analyzed at the magni�cation of 1 : 1000. Tissues were
harvested from mice inoculated aer 21 days, since the main
changes in lesion progression and cell migration observed in
the �ow cytometry were related to this time, exception to the
cytokeratine positive epithelioid cells, which presented the
more expressive changes aer 7 days of inoculation.
2.9. Flow Cytometry. Two kinds of samples were submitted
to �ow cytometry: in a �rst set of experiments, peritoneal
washing �uids were obtained, for B1/B2 cells counting� in
a second set of experiments, the local lymph node single
cell suspension was obtained, for B1/B2 and T-cell subsets
counting.
In the �rst set, mice were euthanized using a CO2 camera
in the 7, 14, and 21 days aer BCG inoculation and the
peritoneal washing was made just aer this procedure. us,
5mL of RPMI medium (GIBCO) were injected into the
peritoneal cavity and a smooth massage was made to allow
the release and homogenization of cells. e washing �uid
was harvested using a plastic Pasteur pipette, transferred to
plastic 15mL Falcon tubes immersed in ice, and centrifuged
at 2000 rpm for 5 minutes.
Since the relevant results obtained from the �rst set of
experiments revealed that the cell changes occurred only in
21 days aer BCG inoculation, in the second set, regarding
the lymph node cell counting, mice were euthanized just aer
this time. us, in the second set of experiments, mice were
euthanized and the popliteal lymph node was harvested and
put inside a drop of 2% PBS/BFS on a Petri plate, maintained
in an ice tray. e cells were suspended with the help of a
scalpel and the suspension was washed with 2% PBS/BFS and
transferred into a 15mL Falcon plastic tube kept immersed
in ice. To obtain enough cells to be measured, �ve lymph
nodes from the same group were used to complete a single
tube and the procedure was repeated twice, in two repetition
blocks. For each tube, the volume of samples was adjusted to
1.5mL and 0.5mL of liberase (ROCHE) previously diluted at
0.1mg/mL was included. e tubes were maintained under
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F 10: (a) Histomorphometric analysis of spleen, showing the mean of follicular area (pixels) and standard deviation, in function of
time. (b) �earls staining positive phagocytes for hemosiderin per �eld (mean, standard deviation) in the subcutaneous tissue of the footpad,
in function of time. �en �elds were counted per slide. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, MANOVA.
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F 11: (a) �otal peritoneal lymphocytes; (b) total peritoneal phagocytes, both �uanti�ed by �ow cytometry in function of time. Data
represented by mean and standard deviation, MANOVA; (c) proportion lymphocyte (grey)/phagocyte (red) at day 21st. Data represented by
the mean of cells harvested from �ve mice per group. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 in relation to control,𝑋𝑋2.
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(c)
F 12: Phagocyte subsets in the peritoneum. (a) number of CD11b+/CD19−mature phagocytes; (b) number of CD11b+/CD19+ double
marked phagocytes (BDP), both quanti�ed by �ow cytometry in function of time. Data represented by mean and standard deviation.
MANOVA. (c) BDP CD11b+/CD19+(grey)/mature phagocyte CD11b+/CD19−(red) proportion at day 21. Data represented by the mean
of cells harvested from �ve mice per group. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 in relation to control,𝑋𝑋2.
T 1: Markers used in the immunohistochemistry.
Marker Cell Supplier Molecular target Clone Origin species/target Dilution
Anti-CD34 Marrow stem cells Serotec CD34 Mec14.7 Rat-mouse 0.5%
Anti-CD3 T cells Serotec CD3 CD3-12 Rat-mouse 1 : 80
Anti-CD11b Migrating phagocytes Serotec CD11b M1/70.15 Rat-mouse 10%
Anti-CD45R B Lymphocytes (speci�cally) Serotec Surface protein (LCA) RA3-6B2 Rat-mouse 0.5%
Anti-cytokeratin Epithelioid cells Serotec Poly-cytokeratin Polyclonal Rabbit-mouse 10 𝜇𝜇g/mL
agitation at 37∘C for 30minutes, in order to get a complete cell
release from tissue debris. Aer this procedure, the samples
were homogenized and �ltered to another tube, using a 70
micra cell �lter (BD) and, then, centrifuged.
Aer centrifugation, cellular pellets from peritoneal �u-
ids and regional popliteal lymph node were suspended in
1mL of ACK hemolytic buﬀer (GIBCO) and incubated for 2
minutes at room temperature.en, 5mL of PBS were added
and the number of viable cells was counted in a modi�ed
Neubauer chamber (HAUSSER SCIENTIFIC).
Cells (𝑃 × 𝑃𝑃6 cells per tube) were centrifuged and
incubated with anti-mouse CD16/CD32 diluted 1 : 100 in
PBS with 1% bovine serum albumin (PBS/BSA) for 20
minutes at 4∘C, to perform the Fc𝛾𝛾 II and III blocking.
en, peritoneal �uids and regional popliteal lymph node
samples were washed and suspended in 200 or 300𝜇𝜇L of
PBS/BSA, being equally divided in two or three microtubes,
respectively. e �rst microtube was incubated without
antibodies and the second contained 1% anti-CD19 APC,
anti-CD23 FITC, anti-CD5 PerCP, and anti-CD11b PE.
e third microtube contained 1% anti-CD25 AF488, anti-
CD4 PE, anti-CD19 PE Cy5.5, and anti-CD8 AF 405 (all
antibodies from INVITROGEN). All of themwere incubated
for about 30 minutes at 4∘C.e last centrifugation was done
and the cells were suspended in 1mL of PBS, ��ed in 1%
paraformaldehide (MERCK), and analyzed by �ow cytom-
etry using FACSCalibur (BD Biosciences, Mountain View,
CA, USA) or the ATTUNE Acoustic Focusing Cytometer
(APPLIED BIOSYSTEM). e Flow Jo 8.7 and the Attune
1.2 soware were used to analyze data, respectively. Ten
thousand events were acquired for each sample.e transpo-
sition of data to EXCEL 2007 and INSTAT 3.0 soware was
made aer all analysis was completed and the raw data were
checked by a third person.
For both, peritoneal and lymph node cells, lumpiness
and cell size were selected to determinate the lymphocyte
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F 13: B-lymphocyte subsets in the peritoneum. (a) number of CD23+/CD19+ B2 cells; (b) number of CD23−/CD19+ B1 cells, both
quanti�ed by �ow cytometry in function of time. Data represented by mean and standard deviation. MANOVA. (c) other lymphocytes
(grey)/B1 (red) proportion; and (d) B1a (grey)/B1b (red) proportion at day 21. Data represented by the mean of cells harvested from �ve
mice per group. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 in relation to control,𝑋𝑋2.
and phagocyte subpopulations. e �uorescence obtained
by the markers was used to establish the speci�c gates of
positive cells. us, from the lymphocyte gate, the B2 cells
were determined by the simultaneous high expression of
CD19 and/or CD23 and the B1 cells were determined by
the high expression of CD19 and CD11b. From this last
subpopulation, the quantity of CD5 positive (B1 a) and CD5
negative (B1 b) cells was calculated. From the phagocyte gate,
double positive cells for CD19 and CD11b were labeled as
“B1-derived phagocytes” (BDP) and CD11b positive—CD19
negative cells were labeled simply as “mature phagocyte”
(Figure 3(a)).
e analysis of T-cells subsets present in the lymph nodes
was made from the lymphocyte gate. e CD19 negative
cells were delimited in a speci�c gate from which the CD4
andCD8 cell subpopulations were determined. An additional
counting was made from each of these subpopulations to
determine the percentage of T reg CD25 positive cells
(Figures 3(b) and 3(c)).
2.10. Statistical Analysis. e data were �rst analyzed by the
Bartlett test to verify the homogeneity of samples and, then,
submitted to Student t-test or Mann-Whitney test according
to the case. e 𝑋𝑋2 test was used to evaluate the proportion
between cell subsets observed in the �ow cytometry and
histomorphometry. e granuloma evolution and histomor-
phometric parameters recorded in function of time were
evaluated by MANOVA. In all cases, the values of 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃
were considered signi�cant in relation to control.
3. Results
3.1. Gross Measurement of Granuloma Lesion. e granu-
loma was macroscopically measured in function of time.e
gross lesion in thymulin 5CH treated mice was bigger than
control from the 10 day aer inoculation, being the peak at
21 days (Figure 4).
3.2. Histopathology. e scores of cytoplasmatic BCG con-
tent obtained from Ziehl-Neelsen staining method revealed
that, at the 21 day aer inoculation, the thymulin 5CH treated
mice showed signi�cant reduction of infection in relation to
control (Figure 5), corresponding to the time of maximum
granuloma development (Figures 4 and 6).
e histopathology of the granuloma analyzed in HE
slides at the 7 day aer inoculation presented less epithelioid
cells and predominance of newly migrated phagocytes in
thymulin 5CH treated mice in relation to control (Figure 6).
e later evaluation of the lesion aer the immunohisto-
chemistry procedures using anticytokeratin antibody to iden-
tify mononuclear positive cells (epithelioid cells) con�rmed,
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(b)
F 14: Lymphocytes subsets obtained from the lymphocyte
gate aer �ow cytometry. Samples harvested at the 21 day aer
BCG inoculation. (a) Proportion between B1 CD11b+/CD19+ cells
(red) and other lymphocytes (grey); (b) proportion between B2
CD11b−/CD19+ cells (red) and T CD11b−/CD19− cells (grey).
Data represented by the average of both blocks of duplicate samples.
∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 in relation to control,𝑋𝑋2.
T 2: Cell counting per �eld using diﬀerent cell markers. Ten
�elds per slide of footpad connective tissue were counted in blind.
Marker Control ymulin 5CH
Anti-CD34 (day 21) 1.787 ± 0.750 𝑃𝑃368 ± 𝑃𝑃54𝑃∗
Anti-CD3 (day 21) 1.600 ± 1.510 2.400 ± 0.540
Anti-CD45R (day 21) 0.800 ± 0.830 0.400 ± 0.540
Anti-CD11b (day 21) 1.765 ± 0.780 1.419 ± 0.587
Anti-cytokeratin
Day 7 5.275 ± 2.172 2𝑃6𝑃𝑃 ± 𝑃𝑃𝑃95∗
Day 21 5.020 ± 2.759 4.42 ± 1.486
Data represent mean ± standard deviation. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃, Mann-Whitney in
relation to control.
quantitatively, this eﬀect. However, this diﬀerence was not
prolonged to the 14 and 21 days (Figures 7 and 8, Table 2).
e number of CD34 positive cells per �eld in the footpad
was also smaller in thymulin 5CH treatedmice in comparison
to the control group, but no diﬀerence between groups
was seen regarding CD11b, CD3, and CD45R positive cells
(Table 2).
e lymph node histomorphometry revealed increase
in germinal center/follicle diameter ratio in thymulin 5CH
treated mice compared to the control group (Figure 9).
e histomorphometrical analysis of the spleen showed
increase in follicle diameter in thymulin 5CH treated mice
at the 7 day aer BCG inoculation, but not at the 14 and
21 days (Figure 10(a)). e Pearls staining method revealed
increase in phagocyte activity of iron pigments in spleen in
thymulin 5CH treated group during all experimental period
(Figure 10(b)).
3.3. Flow Cytometry Analysis
3.3.1. PeritonealWashing. e analysis of peritoneal washing
was split in two sets of data: (a) those from the lymphocyte
gate and (b) those from phagocyte gate (Figure 3(a)). e
total cell counting from each gate revealed an inversion of
both populations in function of time, with increase of the
population presenting phagocyte morphology (higher size
and lumpiness) at the 21 day. is pattern was equal as in
control as in thymulin 5CH treated group, but this last group
showed more intense and signi�cant inversion compared to
the control (Figures 11(a), 11(b), and 11(c)).
e analysis of speci�c phagocyte gate shows a peak of
mature phagocytes at 21 day for both groups (Figure 12(a))
and thymulin 5CH treated mice showed a steady percentage
of B1-derived phagocytes (BDP) at this time, diﬀerent to
the control (Figure 12(b)). us, the proportion between
BDP/mature phagocytes was highlighted in treated animals
(Figure 12(c)). Instead, the lymphocyte gate showed the
inverse behavior: the B1 population was reduced at day 21
in thymulin 5CH treated mice in contrast to the control.
e B2 cells kept their population steady in function of time
(Figures 13(a), 13(b), and 13(c)). Also, a mild reduction
in B1a (CD19+/CD5+)/B1b (CD19+/CD5−) ratio was seen
in thymulin 5CH treated animals aer 21 days from BCG
inoculation (Figure 13(d)).
is opposite behavior between B1 cells in the lympho-
cyte population and B1 cells in the phagocyte population
of the peritoneal cavity indicates the B1 diﬀerentiation into
mature phagocytes.
3.3.2. Lymph Node Cell Suspension. Since the main eﬀects of
thymulin 5CH on peritoneal B1, B2, and phagocytes were
got aer 21 days from BCG inoculation into the footpad,
the analysis of cell suspension harvested from popliteal local
lymph node was focused on this time. Data were also split
in two sets: (a) those from the lymphocyte gate and (b)
those from phagocyte gate. From the lymphocyte gate, a
supplementary data was obtained by counting T-cells subsets
CD19− CD4+ or CD19− CD8+ (Figures 3(b) and 3(c)).
ebalance of cells subsets present in the lymphocyte gate
has shown that thymulin 5CH treated mice presented more
double positive B1 (CD11b+ CD19+) and double negative
T (CD11b− CD19−) cells regarding to B2 (CD11b− CD19+)
cells, comparing to the control (Figures 14(a) and 14(b)). No
diﬀerence was seen in relation to B1a/B1b ratio or in relation
to CD4+/CD8 ratio (Figures 15(a) and 15(b)). Traces of T
reg CD25+ cells were seen in both groups, without statistical
signi�cance between groups (ymulin 5CH= 1.75 ± 0.957;
control = 1.5 ± 1.914 CD25+ cells in 10000 events).
e analysis of phagocyte gate also showed an increase
of double positive BDP (CD11b+ CD19+) cells in relation to
other phagocytes (CD11b+CD19−) in thymulin 5CH treated
group (Figures 16(a) and 16(b)).
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F 15: B1- and T-lymphocyte subsets obtained from the lym-
phocyte gate aer �ow cytometry. Samples harvested at the
21 day aer BCG inoculation. (a) proportion between B1a
CD11b+/CD19+/CD5+ cells (red) and B1b CD11b+/CD19+/CD5−
cells (grey); (b) proportion betwen T CD4+ cells (red) and T CD8+
cells (grey). Data represented by the average of both blocks of
duplicate samples,𝑋𝑋2.
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F 16: Cells obtained from the phagocyte gate aer �ow
cytometry. Samples harvested at the 21 day aer BCG inoculation.
(a) Proportion between BDP CD11b+/CD19+ cells (red) and other
phagocytes CD11b+/CD19− (grey). ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃𝑃𝑃 in relation to
control. Data represented by the average of both blocks of duplicate
samples,𝑋𝑋2.
4. Discussion
Mice treated with thymulin 5CH presented a particular
kinetic of cell migration toward the BCG-induced granu-
loma. In the �rst seven days, more young mononuclear cells
and less epithelioid cells were identi�ed in the in�ammation
focus, in comparison to the control, which was con�rmed by
immunohistochemistry. At the same time, higher phagocytic
activity was observed in spleen macrophages too, whose
pattern lasted up to the 21 day. is indicates that thymulin
5CH treatment is able to modulate the central and local
innate immune response since its early phase. In spleen,
probably the local macrophages were the responsible to this
increase in phagocytic activity, but the hypothesis of B1-cells
migration from the peritoneum to the spleen followed by
phagocyte diﬀerentiation cannot be ignored [39, 40].
B-1 cells constitute a unique B-cell population with dis-
tinct ontogenic, phenotypic, and functional characteristics.
ese cells found preferentially in peritoneal and pleural
cavities of adult mice are partially similar to B-2 cells because
of the expression of CD19, IgM, and IgD but not CD23. B-
1 cells have been described as a promiscuous cell lineage
because of the co-expression of myeloid markers, such as
CD11b.e expression of CD5determines two subtypes of B-
1 cells: B-1a (CD5+) e B-1b (CD5−) [41–44]. Diﬀerent groups
have already demonstrated that B-1 cells can diﬀerentiate into
mononuclear phagocytes and tomigrate to in�ammatory foci
in vivo, suggesting the involvement of these cells in essential
immune mechanisms, as in�ammatory responses [36, 45–
47].
In the current study, aer 21 days from BCG inoculation,
themost intense innate immune responsemodi�cations were
seen. Treated mice presented exuberant gross subcutaneous
lesion and the phenotypic features of the present cells showed
less CD34+ bone-marrow-derived cells per �eld, compar-
ing to control, corroborating the hypothesis of phagocyte
migration from alternative hematopoietic sites to the local
infection, which decreased faster in treated than in control
mice.
In the local lymph node of thymulin 5CH treated mice,
higher germinal center/follicle diameter ratio could also
be seen, suggesting lymphocyte collaboration in the local
response regulation. In fact, at the �ow cytometry analysis,
an increase in the T-cells population was seen in relation
to B cells. On the other hand, an increase of B1 cells could
also be seen in relation to the other lymphocyte subtypes. In
the phagocyte population, treated mice showed more BDP
(CD19+/CD11b+ phagocytes) [34] among them, comparing
to the control. Maybe in control group the main source of
phagocytes had been the bone-marrow-derived monocytes
or even the same B1 peritoneal cells in a slowly migration
kinetic, in order to give time tomigrated cells to lack its ability
to express CD19, as have been described before [35, 45].
Considering that B-1 cells are the main source of B-cell-
derived IL-10 [41], a putative modulation role of B1 cells in
the lesion site over the other phagocytes in thymulin 5CH
treated mice cannot be disregarded, probably by paracrine
secretion of IL-10 [48, 49]; this hypothesis deserves further
investigation.
At the same time, 21 days, in the peritoneum, the balance
of resident cells showedmoremacrophages than lymphocytes
in treated mice. Analyzing each population, it could be
seen more B1-derived phagocytes and less B1 lymphocytes,
suggesting phagocyte diﬀerentiation of B1 stem cells. It is
corroborated by the increase in the percentage of B1b cells
in relation to B1a cells. It is known that B1b cells can
diﬀerentiate spontaneously into phagocyte in vitro [34] and
in vivo [46], even though B1a can also do it when properly
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stimulated by in�ammatory signals [50–52]. On the other
hand, both B1a and B1b could also secrete antibodies (IgM,
IgA), naturally (B1a) or signaling-induced (B1b) [44, 47].
Taking the data together, it seems that, thymulin 5CH
triggers a sequence of coordinated systemic physiological
eﬀects. During the 21 days of observation, the trend of B1
peritoneal cells to diﬀerentiate into phagocyte and to migrate
into local lymph node, near to the subcutaneous granuloma,
is more evident in thymulin 5CH treated mice. Besides the
natural site of B1 cells is the peritoneum, no B1 cell is
seen in lymph nodes in basal conditions [53]. However, the
characterization of a solid population of B1 cells in the local
lymph node (Figure 3(b)) indicates theirmigration to this site
in treated mice. e peritoneal B1-cells migration to remote
in�ammation sites, including BCG-induced granuloma cell
population is well described in the literature, [38, 45, 54], as
well as the higher phagocytic/antigen presentation activities
in phagocytes derived from peritoneal B1 cells in mice
[55].
e increase of local lymph node T lymphocytes also
suggests some collaboration of these cells in this process and
the �nal result is the improvement of infection remission, as
seen in Figure 5. Indeed, T-cell collaboration to B1 cells was
already described in other pathological conditions, such as
tissue allogra rejection and experimental visceral leishma-
niasis [56]. Regarding the B2 peritoneal cells, thymulin 5CH
treated mice presented a trend to keep its levels constant,
avoiding the decline observed in the control. Although
the mechanism of B2 control by thymulin 5CH remains
unknown, a natural hypothesis that emerges from our results
is the possibility to have at least part of the peritoneal B1 cells
diﬀerentiated into B2 cells, instead of phagocytes. It is known
that this kind of diﬀerentiation can be done in vivo, according
to the in�ammatory signals context, for instance, in absence
of galectin-3 or in the presence of signals mediated by Toll-
like receptors [57, 58].
e modulation action of homeopathic thymulin prepa-
rations over lymphocytes is known since the eighties [15,
59], although very few articles are found in the literature
about and little is known about which methods of thymulin
preparation were used and how was the zinc concentra-
tion. About the use of nonhomeopathic very low doses of
serum thymic factor, classical studies performed in radiation-
induced immune de�ciency show that low doses are more
eﬀective than higher ones [60, 61], however, in these studies,
doses varied from 3 to 500 micrograms. e eﬀects observed
in the present followed a quite lower dose than those
described before: thymulin 5CH (4 × 10−13M or 0.4 ng in
the water bottle) was oﬀered into the drinking water reaching
a dose equivalent to 4 pg/mouse, which means, 109 times
smaller than that described by [22] (10mg/mouse). Also,
diﬀerently to the formers, they were prepared according to
the oﬃcial homeopathic method, as described in speci�c
pharmacopeias. How these homeopathic ultra high dilutions
act upon biological systems is still unknown, but some
recent studies suggest the participation of nanostructures in
homeopathic preparations beyond Avogadro’s number [62,
63]. Further studies about the determination of a putative
ideal dose/homeopathic potency of serum thymic factor in
mice challenged with BCG or other infectious agents can still
be done, using potency-eﬀect correlations, even including
those above 10−23M [4].
Additionally, the present results still open a new and
original point of view about thymulin 5CH eﬀect: the ability
of homeopathic very high diluted zinc-free serum thymic
factor to increase phagocyte diﬀerentiation from mouse
peritoneal B1 cells.
Recently, an experimental study performed by our group
in a commercial broiler chicken breeding revealed the impact
of the immune modulation eﬀect of thymulin 5CH on the
lymphoid organs histology and on the productivity index
(based on weight gain), showing an interesting usefulness
of homeopathic preparations as a zoo technical tool [13].
Besides serum thymic factor, high dilutions eﬀects on in�am-
mation by other endogenous and exogenous immune mod-
ulating substances were also described, such as bursin [64],
glucocorticoid [11, 65], and plant extracts [66, 67]. All these
substances, when in high diluted homeopathic preparation,
may represent potential tools for these technical purposes.
e global analysis of the results corroborate the previ-
ously described immune modulating eﬀect of high diluted
thymulin 5CH [13] and adds important new information
about the granuloma cell in�ux control and the phago-
cyte eﬃciency, observed by the BCG infection remission.
Although B1 cells have not been described in humans,
the present results also invite us to consider the putative
bene�ts of homeopathic high diluted serum thymic factor
when associated to BCG human vaccination or to traditional
treatment of naturalMycobacterium sp infection.
�on��ct of �nterests
is project was analyzed by the Bioethical Research commit-
tee of Universidade Paulista (protocol UNIP 007/10) and is in
accordance to the Brazilian laws of animal protection. ere
is no con�ict of interests related to this research protocol.
Acknowledgments
anks to FAPESP (2010/50842-0), UNIP, and CAPES-
PROSUP for funding. anks to Boiron Brasil Laboratory
for thymulin 4CH supplying. anks to Butantan Institute
for BCG supplying.anks to Paulo Ailton Vedovato, Wilton
Pereira dos Santos, and Michelle Sanchez Correa for the
technical support.
References
[1] R. van Wijk, J. Clausen, and H. Albrecht, “e rat in basic
therapeutic research in homeopathy,” Homeopathy, vol. 98, no.
4, pp. 280–286, 2009.
[2] A. R. Khuda-Bukhsh, “Mice as a model for homeopathy
research,” Homeopathy, vol. 98, no. 4, pp. 267–279, 2009.
[3] L. V. Bonamin and P. C. Endler, “Animal models for studying
homeopathy and high dilutions: conceptual critical review,”
Homeopathy, vol. 99, no. 1, pp. 37–50, 2010.
Evidence-Based Complementary and Alternative Medicine 13
[4] P. Endler, K. ieves, C. Reich et al., “Repetitions of funda-
mental researchmodels for homeopathically prepared dilutions
beyond 10−23: a bibliometric study,” Homeopathy, vol. 99, no. 1,
pp. 25–36, 2010.
[5] P. Bellavite, A. Conforti, V. Piasere, and R. Ortolani, “Immunol-
ogy and homeopathy. 1. Historical background,” Evidence-
Based Complementary and Alternative Medicine, vol. 2, no. 4,
pp. 441–452, 2005.
[6] P. Bellavite, A. Conforti, F. Pontarollo, and R. Ortolani,
“Immunology and homeopathy. 2. Cells of the immune system
and in�ammation,” Evidence-Based Complementary and Alter-
native Medicine, vol. 3, no. 1, pp. 13–24, 2006.
[7] P. Bellavite, R. Ortolani, and A. Conforti, “Immunology and
homeopathy. 3. Experimental studies on animal models,”
Evidence-Based Complementary and Alternative Medicine, vol.
3, no. 2, pp. 171–186, 2006.
[8] P. Bellavite, R. Ortolani, F. Pontarollo, V. Piasere, G. Benato,
and A. Conforti, “Immunology and homeopathy. 4. Clinical
studies—part 2,” Evidence-Based Complementary and Alterna-
tive Medicine, vol. 3, no. 4, pp. 397–409, 2006.
[9] P. Bellavite, R. Ortolani, F. Pontarollo, G. Pitari, andA. Conforti,
“Immunology and homeopathy. 5. e rationale of the ‘Simile’,”
Evidence-Based Complementary and Alternative Medicine, vol.
4, no. 2, pp. 149–163, 2007.
[10] A. Conforti, P. Bellavite, S. Bertani, F. Chiarotti, F. Menniti-
Ippolito, and R. Raschetti, “Rat models of acute in�ammation:
a randomized controlled study on the eﬀects of homeopathic
remedies,” BMC Complementary and Alternative Medicine, vol.
7, article 1, 2007.
[11] L. V. Bonamin, K. S. Martinho, A. L. Nina, F. Caviglia, and R.
G.W. Do Rio, “Very high dilutions of dexamethasone inhibit its
pharmacological eﬀects in vivo,”Homeopathy, vol. 90, no. 4, pp.
198–203, 2001.
[12] J. R. Guedes, S. Carrasco, C. M. Ferreira et al., “Ultra high
dilution of triiodothyroninemodi�es cellular apoptosis in Rana
catesbeiana tadpole tail in vitro,” Homeopathy, vol. 100, no. 4,
pp. 220–227, 2011.
[13] C. Sato, V. G. Listar, and L. V. Bonamin, “Development of
broiler chickens aer treatment with thymulin 5cH: a zoo
technical approach,” Homeopathy, vol. 101, no. 1, pp. 68–73,
2012.
[14] K. S. Martinho, V. D. B. de Bento, G. U. Benvenga, V. A.
Marcondes, and L. V. Bonamin, “Hepatic cell growth models
for the study of ultra high dilutions,” in Signal and Images:
Contributions and Contradictions About HighDilution Research,
L. V. Bonamin, Ed., pp. 83–96, Springer, Dordrecht, e
Netherlands, 2008.
[15] V. Daurat, P. Dorfman, and M. Bastide, “Immunomodulatory
activity of low doses of interferon 𝛼𝛼,𝛽𝛽 in mice,” Biomedicine and
Pharmacotherapy, vol. 42, no. 3, pp. 197–206, 1988.
[16] M. Bastide, V. Daurat, M. Doucet-Jaboeuf, A. Pelegrin, and
P. Dorfman, “Immunomodulator activity of very low doses of
thymulin in mice,” International Journal of Immunotherapy, vol.
3, no. 3, pp. 191–200, 1987.
[17] M. Bastide, M. Doucet-Jaboeuf, and V. Daurat, “Activity
and chronopharmacology of very low doses of physiologi-
cal immune inducers,” Immunology Today, vol. 6, no. 8, pp.
234–235, 1985.
[18] M. Guennoun, F. Boudard, C. Cabaner, Y. Robbe, J. B. Dubois,
and M. Bastide, “Radioprotection and immune system regen-
eration of irradiated mice by using high dilution treatment,”
Chronobiology International, vol. 14, supplement 1, article 60,
1997.
[19] R. L. Toledo, Associação timulina-isoterápico de ciclofosfamida
no tratamento de camundongos portadores de tumor de Erlich,
Research Center—UNIP, Universidade Paulista, São Paulo,
Brazil, 2005.
[20] F. R. M. Soto, E. R. Vuaden, C. D. Coelho, N. R. Benites, L. V.
Bonamin, and S. S. de Azevedo, “A randomized controlled trial
of homeopathic treatment of weaned piglets in a commercial
swine herd,” Homeopathy, vol. 97, no. 4, pp. 202–205, 2008.
[21] J. F. Bach, M. Dardenne, J. M. Pleau, and M. A. Bach,
“Isolation, biochemical characteristics, and biological activity of
a circulating thymic hormone in the mouse and in the human,”
Annals of the New York Academy of Sciences, vol. 249, pp.
186–210, 1975.
[22] K. Inagaki-Ohara, N. Kobayashi, H. Nishimura et al., “Eﬀects
of a nonapeptide thymic hormone on intestinal intraep-
ithelial lymphocytes in mice following administration of 5-
�uorouracil,” Cellular Immunology, vol. 171, no. 1, pp. 30–40,
1996.
[23] O. A. Brown, Y. E. Sosa, M. Dardenne, J. M. Pléau, and R.
G. Goya, “Studies on the gonadotropin-releasing activity of
thymulin: changes with age,” Journals of Gerontology Series A,
vol. 55, no. 4, pp. B170–B176, 2000.
[24] M. Dardenne, “Role of thymic peptides as transmitters between
the neuroendocrine and immune systems,” Annals of Medicine,
vol. 31, supplement 2, pp. 34–39, 1999.
[25] M. Dardenne, N. Saade, and B. Sa�eh-Garabedian, “Role of
thymulin or its analogue as a new analgesicmolecule,”Annals of
the New York Academy of Sciences, vol. 1088, pp. 153–163, 2006.
[26] P. C. Reggiani, G. R. Morel, G. M. Cónsole et al., “e
thymus-neuroendocrine axis: physiology, molecular biology,
and therapeutic potential of the thymic peptide thymulin,”
Annals of the New York Academy of Sciences, vol. 1153, pp.
98–106, 2009.
[27] L. Santarelli, M. Bracci, and E. Mocchegiani, “In�uence of mer-
cury on thymulin production: metallothioneins role,” Giornale
Italiano di Medicina del Lavoro ed Ergonomia, vol. 27, no. 3, pp.
335–338, 2005.
[28] B. Kallen, M. Dohlsten, and H. Klementsson, “Eﬀect of
cyclophosphamide pretreatment on autoimmune encephalo-
myelitis in rats,” Acta Neurologica Scandinavica, vol. 73, no. 4,
pp. 338–344, 1986.
[29] N. Hirai, H. Furuyama, A. Awaya, and M. Onuma, “Eﬀect of
administration of serum thymic factor (FTS) in calves and
rabbits infected with bovine immunode�ciency-like virus.,”e
Journal of VeterinaryMedical Science, vol. 57, no. 2, pp. 307–310,
1995.
[30] N. Saitoh, A. Awaya, A. Sakudo et al., “Serum thymic factor
prevents LPS-induced pancreatic cell damage in mice via up-
regulation of Bcl-2 expression in pancreas,” Microbiology and
Immunology, vol. 48, no. 9, pp. 629–638, 2004.
[31] J. Yasuda, W. Nishioka, A. Sakudo et al., “Suppressor mech-
anism of serum thymic factor on tumor necrosis factor-𝛼𝛼-
induced apoptosis in the mouse pancreatic 𝛽𝛽-cell line,” Bio-
chemical and Biophysical Research Communications, vol. 311,
no. 2, pp. 501–505, 2003.
[32] H.Aono,M.Morishita,M. Sasano et al., “Amelioration of type II
collagen induced arthritis in rats by treatment with thymulin,”
Journal of Rheumatology, vol. 24, no. 8, pp. 1564–1569, 1997.
[33] A. F. Vigna, S. R. Almeida, P. Xander, E. Freymüller, M. Mar-
iano, and J. D. Lopes, “Granuloma formation in vitro requires
14 Evidence-Based Complementary and Alternative Medicine
B-1 cells and ismodulated by Paracoccidioides brasiliensis gp43
antigen,”Microbes and Infection, vol. 8, no. 3, pp. 589–597, 2006.
[34] A. F. Popi, F. L. T. Motta, R. A. Mortara, S. Schenkman,
J. D. Lopes, and M. Mariano, “Co-ordinated expression of
lymphoid and myeloid speci�c transcription factors during B-
1b cell diﬀerentiation into mononuclear phagocytes in vitro,”
Immunology, vol. 126, no. 1, pp. 114–122, 2009.
[35] A. F. Popi, D. S. Zamboni, R. A. Mortara, and M. Mariano,
“Microbicidal property of B1 cell derived mononuclear phago-
cyte,” Immunobiology, vol. 214, no. 8, pp. 664–673, 2009.
[36] H. C. Oliveira, A. F. Popi, A. L. L. Bachi, S. Nonogaki, J. D.
Lopes, and M. Mariano, “B-1 cells modulate the kinetics of
wound-healing process in mice,” Immunobiology, vol. 215, no.
3, pp. 215–222, 2010.
[37] M. F. Nogueira-Martins andM.Mariano, “B-1 cell participation
in T-cell-mediated alloimmune response,” Immunobiology, vol.
215, no. 4, pp. 264–274, 2010.
[38] R. T. Russo and M. Mariano, “B-1 cell protective role in
murine primaryMycobacteriumbovis bacillus Calmette-Guerin
infection,” Immunobiology, vol. 215, no. 12, pp. 1005–1014,
2010.
[39] H. Ohdan, K. G. Swenson, H. S. Kruger Gray et al., “Mac-
1-negative B-1b phenotype of natural antibody-producing
cells, including those responding to Gal𝛼𝛼1,3Gal epitopes 𝛼𝛼1,3-
galactosyltransferase-de�cient mice,” Journal of Immunology,
vol. 165, no. 10, pp. 5518–5529, 2000.
[40] T. Kawahara, H. Ohdan, G. Zhao, Y. G. Yang, and M. Sykes,
“Peritoneal cavity B cells are precursors of splenic IgM natural
antibody-producing cells,” Journal of Immunology, vol. 171, no.
10, pp. 5406–5414, 2003.
[41] L. A. Herzenberg, A. M. Stall, and P. A. Lalor, “e LY-1 B cell
lineage,” Immunological Reviews, vol. 93, pp. 81–102, 1986.
[42] N. Baumgarth, “e double life of a B-1 cell: self-reactivity
selects for protective eﬀector functions,” Nature Reviews
Immunology, vol. 11, no. 1, pp. 34–46, 2011.
[43] A. O’Garra, R. Chang, N. Go, R. Hastings, G. Haughton, andM.
Howard, “Ly-1B (B-1) cells are themain source of B cell-derived
interleukin 10,” European Journal of Immunology, vol. 22, no. 3,
pp. 711–717, 1992.
[44] B. Roy, S. Shukla,M. Łyszkiewicz et al., “Somatic hypermutation
in peritoneal B1b cells,”Molecular Immunology, vol. 46, no. 8-9,
pp. 1613–1619, 2009.
[45] S. R. Almeida, L. S. Aroeira, E. Frymuller et al., “Mouse B-1
cell-derived mononuclear phagocyte, a novel cellular compo-
nent of acute non-speci�c in�ammatory exudate,” International
Immunology, vol. 13, no. 9, pp. 1193–1201, 2001.
[46] A. F. Popi, L. Osugui, K. R. Perez, I. M. Longo-Maugéri, and
M. Mariano, “Could a B-1 cell derived phagocyte, “be one” of
the peritoneal macrophages during LPS-driven in�ammation�”
PLoS ONE, vol. 7, no. 3, Article ID e34570, 2012.
[47] K. M. Haas, J. C. Poe, D. A. Steeber, and T. F. Tedder, “B-1a and
B-1b cells exhibit distinct developmental requirements andhave
unique functional roles in innate and adaptive immunity to S.
pneumoniae,” Immunity, vol. 23, no. 1, pp. 7–18, 2005.
[48] A. F. Popi, J. D. Lopes, and M. Mariano, “Interleukin-10
secreted by B-1 cells modulates the phagocytic activity of
murine macrophages in vitro,” Immunology, vol. 113, no. 3, pp.
348–354, 2004.
[49] S. Garaud, C. le Dantec, A. R. de Mendoza, R. A. Mageed, P.
Youinou, and Y. Renaudineau, “IL-10 production by B Cells
expressing CD5with the alternative exon 1B,”Annals of the New
York Academy of Sciences, vol. 1173, pp. 280–285, 2009.
[50] M. A. Borrello and R. P. Phipps, “Fibroblast-secreted
macrophage colony-stimulating factor is responsible for
generation of biphenotypic B/macrophage cells from a subset
of mouse B lymphocytes,” Journal of Immunology, vol. 163, no.
7, pp. 3605–3611, 1999.
[51] M. A. Borrello and R. P. Phipps, “e B/macrophage cell: an
elusive link between CD5+ B lymphocytes and macrophages,”
Immunology Today, vol. 17, no. 10, pp. 471–475, 1996.
[52] M. A. Borrello and R. P. Phipps, “Fibroblasts support outgrowth
of splenocytes simultaneously expressing B lymphocyte and
macrophage characteristics,” Journal of Immunology, vol. 155,
no. 9, pp. 4155–4161, 1995.
[53] A. Itakura, M. Szczepanik, R. A. Campos et al., “An hour
aer immunization peritoneal B-1 cells are activated to migrate
to lymphoid organs where within 1 day they produce IgM
antibodies that initiate elicitation of contact sensitivity,” Journal
of Immunology, vol. 175, no. 11, pp. 7170–7178, 2005.
[54] H. Moon, J. G. Lee, S. H. Shin, and T. J. Kim, “LPS-induced
migration of peritoneal B-1 cells is associated with upregulation
of CXCR4 and increased migratory sensitivity to CXCL12,”
Journal of Korean Medical Science, vol. 27, no. 1, pp. 27–35,
2012.
[55] J. S. Mussalem, C. C. Squaiella-Baptistão, D. Teixeira et al.,
“Adjuvant eﬀect of killed Propionibacterium acnes on mouse
peritoneal B-1 lymphocytes and their early phagocyte diﬀeren-
tiation,” PLoS ONE, vol. 7, no. 3, Article ID e33955, 2012.
[56] J. W. Moore, L. Beattie, J. E. Dalton et al., “B cell: T cell inter-
actions occur within hepatic granulomas during experimental
visceral leishmaniasis,” PLoS ONE, vol. 7, no. 3, Article ID
e34143, 2012.
[57] S. A. Ha, M. Tsuji, K. Suzuki et al., “Regulation of B1 cell
migration by signals through toll-like receptors,” Journal of
Experimental Medicine, vol. 203, no. 11, pp. 2541–2550, 2006.
[58] F. L. Oliveira, R. Chammas, L. Ricon et al., “Galectin-3 regulates
peritoneal B1-cell diﬀerentiation into plasma cells,” Glycobiol-
ogy, vol. 19, no. 11, pp. 1248–1258, 2009.
[59] M. Doucet-Jaboeuf, J. Guillemain, and M. Piechaczyk, “Limit-
dose evaluation of serum thymic factor activity,” Comptes
Rendus des Seances de l’Academie des Sciences—Series III, vol.
295, no. 4, pp. 283–286, 1982.
[60] H. Kobayashi, H. Abe, T. Ueyama, A. Awaya, and M. Shikita,
“Radioprotective eﬀects of serum thymic factor in mice,”
Radiation Research, vol. 129, no. 3, pp. 351–356, 1992.
[61] H. Kobayashi, H. Abe, H. Inano, andM. Shikita, “Serum thymic
factor as a radioprotective agent promoting survival aer X-
irradiation,” Experientia, vol. 46, no. 5, pp. 484–486, 1990.
[62] P. S. Chikramane, A. K. Suresh, J. R. Bellare, and S. G. Kane,
“Extreme homeopathic dilutions retain starting materials: a
nanoparticulate perspective,” Homeopathy, vol. 99, no. 4, pp.
231–242, 2010.
[63] I. R. Bell and M. Koithan, “A model for homeopathic remedy
eﬀects: low dose nanoparticles, allostatic cross-adaptation, and
time-dependent sensitization in a complex adaptive system,”
BMC Complementary and Alternative Medicine, vol. 12, no. 1,
article 191, 2012.
[64] B. J. Youbicier-Simo, F. Boudard, M. Mékaouche, J. D. Baylé,
and M. Bastide, “A role for bursa fabricii and bursin in the
ontogeny of the pineal biosynthetic activity in the chicken,”
Journal of Pineal Research, vol. 21, no. 1, pp. 35–43, 1996.
[65] L. V. Bonamin, C. Landi de Moraes, F. Sanches et al., “Rats
born to mothers treated with dexamethasone 15 cH present
Evidence-Based Complementary and Alternative Medicine 15
changes in modulation of in�ammatory process,” Evidence-
Based Complementary and Alternative Medicine, vol. 2012,
Article ID 710923, 10 pages, 2012.
[66] C. M. V. Pedalino, F. F. Perazzo, J. C. T. Carvalho, K. S.
Martinho, C. de O Massoco, and L. V. Bonamin, “Eﬀect of
Atropa belladonna and Echinacea angustifolia in homeopathic
dilution on experimental peritonitis,” Homeopathy, vol. 93, no.
4, pp. 193–198, 2004.
[67] A. P. Kawakami, C. Sato, T. N. Cardoso, and L. V. Bonamin,
“In�ammatory process modulation �y homeopathic arnica
montana 6CH: the role of individual variation,” Evidence-Based
Complementary and Alternative Medicine, vol. 2011, Article ID
917541, 12 pages, 2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
